Global Ketorolac Injection Market Size, Share and Trends Analysis Report, By Type (15 mg/ml and 30 mg/ml), By Patient Type (Adult Patients, Geriatric Patients, and Pediatric Patients), By End-User (Hospitals, Clinics, and Others), Forecast (2022-2028)

The global ketorolac injection market is anticipated to grow at a CAGR of nearly 4.5% during the forecast period (2022-2028). Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and is especially recommended for moderate to severe pain. The major factor expected to drive the market growth is its diversified medicinal use. For instance, ketorolac with paracetamol controls pain without affecting respiration in infants. It is used in the treatment of dysmenorrhea, used as eye drop during eye surgery. Pharmaceutical companies are focusing on R&D for ketorolac injection. Moreover, according to an article published in June 2020 by a science direct article, ketorolac can be utilized for the treatment of PAK1-dependent COVID-19 infection and numerous other deadly viruses in the future which is also expected to boost the market growth during the forecast period.

Some major players in the market include Hikma Pharmaceutical plc, Lupin Ltd., and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2019, Lupin Ltd. announced that the company got approval from the US Food and Drug Administration (US FDA) for its phenylephrine and ketorolac intraocular solution, 1%/0.3%. The company added that it is the generic version of Omidria intraocular solution, 1%/0.3%, Omeros Corp. (Omeros). This medication is used for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. The company also declared that phenylephrine and ketorolac intraocular solution, 1%/0.3%, is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Patient Type
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Hikma Pharmaceutical plc, Lupin Ltd., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ketorolac Injection Market Report by Segment

By Type

• 15 mg/ml
• 30 mg/ml

By Patient Type

• Adult Patients
• Geriatric Patients
• Pediatric Patients

By End-User

• Hospitals
• Clinics
• Others

Global Ketorolac Injection Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa